CLINICAL_TRIALS
trial_result
· 2023-01-10
Clinical Trial Update: An Efficacy and Safety Study of Ravulizumab in ALS Participants [Phase 3]
Summary
Phase 3 trial evaluating ravulizumab in Amyotrophic Lateral Sclerosis (ALS) was terminated; results posted in 2023.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Amyotrophic Lateral Sclerosis, ALS | Phase 3 | Status: TERMINATED | Results posted: 2023-01-10